

Nivolumab CheckMate 067

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS


Quality of life



Serious and disabling adverse effects



Other adjustments



Nivolumab CheckMate 067

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers
Therapeutic Indication: Monotherapy for the treatment of advanced melanoma in adults and adolescents 12 years of age and older*
Experimental Arm: Nivolumab
Control Arm: Ipilimumab

